Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2020-02-03 Director's Dealing
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-02-03 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-03 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-03 English
SC 13G/A
Major Shareholding Notification
2020-01-31 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the company's entry into a material definitive agreement related to a rights offering and an investment agreement with a backstop commitment. It includes details about the terms of the preferred stock issuance and related financial arrangements. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is primarily an announcement of a financing event and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief announcement or press release, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2020-01-30 English
FORM 3 SUBMISSION
Director's Dealing
2020-01-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.